Latest Articles

From Registry to Reality: Reduced Stroke Incidence with Agalsidase Beta in Fabry Disease

Tolerability of Accelerated Agalsidase Beta Infusions in Fabry Disease: The SHORTEN Study Analysis

Fabry Disease in Cardiology Practice: From Red Flags to Diagnosis

FLUNITY-HD

The FLUNITY-HD Study is the largest individually randomized influenza vaccine effectiveness study and the first of its kind for an influenza vaccine. The study demonstrates the superior benefit of HD-IIV, specifically developed for older adults, compared with SD-IIV against a wide range of hospitalization outcomes in a prespecified and powered analysis encompassing nearly half a million participants. Providing the high-quality data, this study provides further critical evidence that widespread use of HD-IIV could substantially reduce the burden of influenza on both older adults and healthcare systems globally.

Epidemiology and Healthcare Burden Attributable to Laboratory-Confirmed RSV Cases Among Children Under Five Years Old in Saudi Arabia

An overview of the latest Saudi evidence presented at ESPID 2026.

Real-World Effectiveness of Nirsevimab

The NIRSE-GAL study is an ongoing population-based, prospective, longitudinal study conducted in Galicia, Spain. It includes infants eligible to receive nirsevimab and evaluates its impact on RSV-related outcomes in both inpatient and outpatient healthcare settings.

Healthcare Resource Utilization and Direct Medical Costs of RSV Infection in Children Under Five Years in Saudi Arabia

An overview of the latest Saudi evidence presented at ESPID 2026.

High-Dose inactivated influenza vaccine (HD-IIV) Recommendations

Health authorities and leading medical societies—from the Gulf region to beyond—now preferentially recommend high-dose influenza vaccination for older adults, driven by robust clinical evidence demonstrating superior protection against influenza-related complications